- Home
- DRTS vs VNDA Comparison
DRTS vs VNDA Comparison
Compare DRTS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRTS
- VNDA
- Stock Information
- Founded
- DRTS 2015
- VNDA 2002
- Country
- DRTS Israel
- VNDA United States
- Employees
- DRTS N/A
- VNDA N/A
- Industry
- DRTS Medical/Dental Instruments
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- DRTS Health Care
- VNDA Health Care
- Exchange
- DRTS Nasdaq
- VNDA Nasdaq
- Market Cap
- DRTS 211.7M
- VNDA 237.9M
- IPO Year
- DRTS N/A
- VNDA 2006
- Fundamental
- Price
- DRTS $2.81
- VNDA $3.95
- Analyst Decision
- DRTS Strong Buy
- VNDA Strong Buy
- Analyst Count
- DRTS 2
- VNDA 2
- Target Price
- DRTS $8.00
- VNDA $16.50
- AVG Volume (30 Days)
- DRTS 32.7K
- VNDA 508.6K
- Earning Date
- DRTS 05-19-2025
- VNDA 05-07-2025
- Dividend Yield
- DRTS N/A
- VNDA N/A
- EPS Growth
- DRTS N/A
- VNDA N/A
- EPS
- DRTS N/A
- VNDA N/A
- Revenue
- DRTS N/A
- VNDA $201,351,000.00
- Revenue This Year
- DRTS N/A
- VNDA $14.36
- Revenue Next Year
- DRTS N/A
- VNDA $44.53
- P/E Ratio
- DRTS N/A
- VNDA N/A
- Revenue Growth
- DRTS N/A
- VNDA 13.37
- 52 Week Low
- DRTS $1.75
- VNDA $3.85
- 52 Week High
- DRTS $4.39
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- DRTS 54.02
- VNDA 35.66
- Support Level
- DRTS $2.57
- VNDA $3.94
- Resistance Level
- DRTS $3.00
- VNDA $4.51
- Average True Range (ATR)
- DRTS 0.16
- VNDA 0.17
- MACD
- DRTS 0.03
- VNDA -0.04
- Stochastic Oscillator
- DRTS 50.02
- VNDA 5.71
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.